UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $31.05 Million Stake in Repligen Co. (NASDAQ:RGEN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 41.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 208,610 shares of the biotechnology company's stock after selling 145,254 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.37% of Repligen worth $31,045,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Champlain Investment Partners LLC increased its stake in Repligen by 149.0% in the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company's stock valued at $211,464,000 after buying an additional 850,345 shares during the period. Thrivent Financial for Lutherans increased its stake in shares of Repligen by 240.5% in the second quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company's stock worth $75,866,000 after acquiring an additional 425,061 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Repligen by 21.0% during the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company's stock worth $172,749,000 after acquiring an additional 237,884 shares in the last quarter. Conestoga Capital Advisors LLC boosted its position in Repligen by 26.7% during the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company's stock valued at $119,363,000 after purchasing an additional 199,322 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Repligen by 39.4% in the second quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company's stock valued at $54,149,000 after purchasing an additional 121,305 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Anthony Hunt sold 22,191 shares of the business's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. The trade was a 13.70 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.20% of the stock is owned by company insiders.

Repligen Stock Performance

RGEN traded down $6.83 during trading on Thursday, hitting $142.26. The stock had a trading volume of 443,658 shares, compared to its average volume of 661,336. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $211.13. The company has a 50 day simple moving average of $141.38 and a 200-day simple moving average of $142.15. The firm has a market cap of $7.97 billion, a PE ratio of -384.48, a P/E/G ratio of 4.47 and a beta of 0.96.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.09. The business had revenue of $154.87 million during the quarter, compared to analysts' expectations of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm's revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.23 EPS. Analysts expect that Repligen Co. will post 1.52 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Royal Bank of Canada reaffirmed an "outperform" rating and set a $205.00 price target on shares of Repligen in a research note on Thursday, September 26th. Wolfe Research assumed coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a "peer perform" rating for the company. StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a research note on Friday, November 22nd. Finally, Wells Fargo & Company started coverage on shares of Repligen in a research note on Tuesday, August 27th. They issued an "overweight" rating and a $180.00 price objective for the company. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, Repligen currently has a consensus rating of "Moderate Buy" and a consensus price target of $190.25.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.